Clinical Trial Update: Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRD [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating the efficacy of bortezomib for relapsed acute lymphoblastic leukemia and related chemotherapeutic toxicity/MRD context.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• Bortezomib (bortezomib)

Snippet

Sponsor: Hospital General de Mexico | Conditions: Acute Lymphoblastic Leukemia, in Relapse, Chemotherapeutic Toxicity | Phase 4 | Status: UNKNOWN